Sunday, September 6, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· March 11, 2026

CPSS Reports Earnings

View original at nasdaq.com
CPSS Reports Earnings Image source: The Motley Fool. DATE March 11, 2026, 1 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Charles BradleyChief Financial Officer — Danny BharwaniChief Operating Officer — Michael Lavin Need a quote from a Motley Fool analyst?…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Employee costs as percentage of portfolio declined from 2.6% to 2.4% despite 8.24% portfolio growth, showing proper scaling

    60% confidence
  • 2024 and 2025 vintages showing significantly better credit performance than 2022-2023 vintages due to credit tightening

    60% confidence
  • Portfolio size of nearly $4 billion provides strong industry competitive positioning

    60% confidence
  • Generation 9 credit model increased approvals by 11%, from low 40% range to low 50% range, while maintaining capture rate

    60% confidence
  • Interest rates expected to remain stable or decline, with unemployment steady, creating favorable environment for 2026

    60% confidence
  • 2025 was a very good year, though growth fell short of expectations

    60% confidence
  • Improved portfolio delinquency performance in 2025 despite macroeconomic headwinds is a significant accomplishment

    60% confidence
  • Minimum portfolio size of $1 billion needed to be competitive in subprime auto lending industry

    60% confidence
  • CPSS ranks among the best credit performers in subprime space based on Intex data used by bond investors

    60% confidence
  • Excluding fair value marks, pretax income improved significantly to $21.5 million in 2025 from $6.4 million in 2024

    60% confidence
  • Recoveries expected to normalize to low 40% range once 2022-2023 vintages run off by end of 2026

    60% confidence
  • 2026 goals focus on portfolio growth, margin improvement through better interest rates, and improved performance by eliminating 2022-2023 vintages

    60% confidence
  • Legacy 2022-2023 loans that were unprofitable represented nearly 40% of portfolio at start of 2025, expected to become de minimis by end of 2026

    60% confidence
  • Credit is readily available and multiple banks are eager to lend or buy CPSS bonds

    60% confidence
  • GLS acquisition set favorable valuation benchmark for subprime auto lending industry

    60% confidence
  • Prime lending program growth will be gradual, similar to near-prime program that eventually reached 5-6% of originations

    60% confidence
  • Interest income growth of 16% year-over-year is the main driver of total revenue increase

    60% confidence
  • 2025 originations of $1.638 billion made it the third-best year in company's 35-year history despite headwinds

    60% confidence
  • Core operating expenses declined as percentage of managed portfolio from 5.6% to 4.8%, demonstrating scaling benefits

    60% confidence
  • Target to increase monthly application volume from 250,000 to 325,000

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com